SLDB, US83422E2046

Solid Biosciences stock: H.C. Wainwright keeps USD 25.00 target for Solid Biosciences stock

Published on 10/28/2026 at 07:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Five FALCON participants had received SGT-212 by October 5, 2026. The Q1 2027 data milestone concerns Solid Biosciences stock.

Regulatory status and trial milestones

Solid Biosciences received EU orphan designation for SGT-212 on October 26, 2026.
Five participants had received SGT-212 by October 5, 2026.
Solid Biosciences expects initial FALCON data in the first quarter of 2027.

SLDB, US83422E2046, Illustration mit AI erstellt.

Solid Biosciences (ISIN US83422E2046) said on October 26, 2026 that five participants had received SGT-212 in the Phase 1b FALCON trial. The European Commission granted orphan designation to the Friedreich's ataxia therapy, according to Solid Biosciences. Investing.com reported on October 27, 2026 that H.C. Wainwright reiterated a Buy rating and a USD 25.00 price target.

Three dated pipeline steps

Solid's recent development path moved from financial execution to clinical visibility. On August 6, 2026, the company reported a second-quarter loss of USD 0.38 per share against a consensus loss of USD 0.46, a USD 0.08 difference, according to MarketBeat. On October 20, 2026, Solid announced seven accepted abstracts for the European Society of Gene and Cell Therapy congress, as stated in its company release. The October 26, 2026 orphan designation and five dosed FALCON participants form the latest step, according to GlobeNewswire.

What does the designation change?

The European designation gives SGT-212 access to reduced regulatory fees, scientific and protocol assistance, and 10 years of EU market exclusivity if the treatment is approved. That benefit is regulatory rather than commercial today, so the clinical readout remains the more important milestone for the investment case.

Next clinical dates

The ESGCT congress schedule lists poster sessions for October 28, 2026, and October 29, 2026, including work on SGT-003, capsid engineering and manufacturing, according to the October 20 company release. Solid also expects initial FALCON clinical data in the first quarter of 2027. The company said the trial is evaluating safety and tolerability in adults aged 18 to 40 with Friedreich's ataxia.

Clinical evidence remains next

For Solid Biosciences, the latest regulatory designation expands the potential development support around SGT-212, while five treated participants provide the immediate clinical reference point. The first-quarter 2027 FALCON data should add the next quantified evidence to that regulatory progress.